By Fineline Cube 
Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading provider of diagnostic and therapeutic medical technology, to acquire Laborie’s JADA System for a total consideration of USD 465 million.
Transaction Overview
- Purchase Price – USD 465 million, representing 6.5× JADA’s trailing‑12‑month revenues and reflecting the rapid U.S. market uptake since its FDA approval.
- Structure – All‑cash transaction; Organon will assume all related regulatory and operational liabilities associated with the JADA System.
- Expected Closing – First quarter of 2026, pending customary regulatory and shareholder approvals.
Background of the JADA System
- Origin – Originally acquired by Organon in June 2021 through the Alydia Health acquisition.
- Clinical Value – Low‑level vacuum‑based therapy that induces physiological uterine contraction to control postpartum hemorrhage (PPH).
- Regulatory Milestones – First FDA clearance in August 2020; technology update clearance in September 2021, enabling wider clinical deployment.
The JADA System has become a cornerstone in obstetric care, with its proven safety profile and demonstrated efficacy across multiple U.S. clinical settings.
Strategic Rationale
- For Organon – Strengthens its medical devices portfolio, particularly in high‑impact peri‑partum care, and expands its footprint in the obstetric therapeutic market.
- For Laborie – Provides liquidity and access to broader market opportunities while allowing Laborie to refocus on its core diagnostic and therapeutic platforms.
- Market Impact – The deal underscores growing investor confidence in post‑partum hemorrhage solutions and in the broader therapeutic device market.
Forward‑Looking Statements
The information herein contains forward‑looking statements regarding the anticipated performance of the JADA System, regulatory approvals, and the success of the transaction. Actual results may differ materially.-Fineline Info & Tech